Business description
PAION AG is a publicly listed Specialty Pharmaceutical Company headquartered in Aachen (Germany) with further sites in Cambridge (United Kingdom) and New Jersey (USA). PAION's lead substance, Remimazolam, is an intravenous ultra-short-acting anesthetic that is currently in Phase III clinical development for procedural sedation and general anesthesia. Remimazolam has been investigated in more than 1,000 patients worldwide. Remimazolam is designed to complement and improve currently available treatment options for patients requiring sedation and anesthesia. PAION is focusing its clinical development activities on Remimazolam and has initiated pre-commercial activities according to PAION's vision to become an acknowledged “PAIONeer” in sedation and anesthesia.
Management board & Supervisory board
| CEO |
| Dr. James Phillips |
| Management board |
| Abdelghani Omari (bis 1.06.2022), Sebastian Werner (ab 1.06.2022) |
| Supervisory board |
| Dr. Jörg Spiekerkötter, Dr. Karin Louise Dorrepaal, Dr. Chris Tanner, Dr. Dr. Irina Antonijevic, Dr. Markus Leyck Dieken |
Company data
| Name: |
PAION AG |
| Address: |
Heussstraße 25,D-52078 Aachen |
| Phone: |
+49-241-4453-0 |
| Fax: |
+49-241-4453-100 |
| E-mail: |
info@paion.de
|
| Internet: |
www.paion.de/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12/31 |
| Free Float: |
88.12% |
| IPO date: |
2/10/2005 |